The trans-Tasman travel bubble is a big plus for AFT, says CEO Hartley Atkinson. AFT Pharmaceutical, maker of painkiller Maxigesic, expects to keep growing this year, particularly if major market Australia can avoid Covid-19 complications. However, investors will have to wait for a dividend as AFT first wanted to reduce its net debt to between $25m and $30m. Most of AFT’s business was in Australia, so the trans-Tasman travel bubble was a big plus, Atkinson​ said. We've used a different approach, we’ve literally hired people straight out of university, and we work really hard to train them.

Source: Stuff May 24, 2021 01:41 UTC